{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:19:56Z","timestamp":1787732396442,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","award":["18-511"],"award-info":[{"award-number":["18-511"]}],"id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ctro.2025.101030","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:23:24Z","timestamp":1754925804000},"page":"101030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative analysis of target volume coverage and liver exposure in high-dose-rate interstitial brachytherapy and in silico MR LINAC-based stereotactic body radiotherapy plans for colorectal liver metastases"],"prefix":"10.1016","volume":"56","author":[{"given":"Sina","family":"Mansoorian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5725-9959","authenticated-orcid":false,"given":"Svenja","family":"Hering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-9753","authenticated-orcid":false,"given":"Jan","family":"Hofmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Weingandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Rottler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3351-8896","authenticated-orcid":false,"given":"Paul","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-7252","authenticated-orcid":false,"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3779-1398","authenticated-orcid":false,"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctro.2025.101030_b0005","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1016\/j.prro.2024.09.011","article-title":"Stereotactic body radiation therapy for liver metastases: systematic review and meta-analysis with international stereotactic radiosurgery society (ISRS) practice guidelines","volume":"15","author":"Franzese","year":"2025","journal-title":"Pract Radiat Oncol"},{"issue":"20","key":"10.1016\/j.ctro.2025.101030_b0010","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1002\/cncr.34931","article-title":"American Radium Society Appropriate Use Criteria for the use of liver-directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines","volume":"129","author":"Hallemeier","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2025.101030_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.800920","article-title":"Narrative review of high-dose-rate interstitial brachytherapy in primary or secondary liver tumors","volume":"12","author":"Karagiannis","year":"2022","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.ctro.2025.101030_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246250","article-title":"Interstitial high-dose-rate brachytherapy of liver metastases in oligometastatic patients","volume":"13","author":"Walter","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctro.2025.101030_b0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13014-021-01812-7","article-title":"Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma","volume":"16","author":"Walter","year":"2021","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2025.101030_b0030","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/cancers13071523","article-title":"Feasibility and early clinical experience of online adaptive MR-guided radiotherapy of liver tumors","volume":"13","author":"Rogowski","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctro.2025.101030_b0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semradonc.2023.10.006","article-title":"The use of MR-guided radiation therapy for liver cancer","volume":"34","author":"Prime","year":"2024","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2025.101030_b0040","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S1470-2045(20)30034-6","article-title":"MRI-guided adaptive radiotherapy for liver tumours: visualising the future","volume":"21","author":"Witt","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2025.101030_b0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2025.101030_b0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"10","key":"10.1016\/j.ctro.2025.101030_b0055","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.3390\/curroncol29100552","article-title":"Dose-volume constraints fOr oRganS At risk In Radiotherapy (CORSAIR): an \u201cAll-in-one\u201d multicenter-multidisciplinary practical summary","volume":"29","author":"Bisello","year":"2022","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2025.101030_b0060","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.prro.2021.03.005","article-title":"Organ at risk dose constraints in SABR: a systematic review of active clinical trials","volume":"11","author":"Gerhard","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2025.101030_b0065","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.brachy.2017.03.005","article-title":"Iridium-knife: another knife in radiation oncology","volume":"16","author":"Milickovic","year":"2017","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.ctro.2025.101030_b0070","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Internat J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.101030_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109448","article-title":"Interfractional dose accumulation for MR-guided liver SBRT: Variation among algorithms is highly patient-and fraction-dependent","volume":"182","author":"Wahlstedt","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.101030_b0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1748-717X-8-175","article-title":"Single-dose radiosurgical treatment for hepatic metastases\u2013therapeutic outcome of 138 treated lesions from a single institution","volume":"8","author":"Habermehl","year":"2013","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2025.101030_b0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/cas.13872","article-title":"Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: a dose escalation study","volume":"110","author":"Makishima","year":"2019","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.ctro.2025.101030_b0090","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.101030_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.prro.2025.05.006","article-title":"Prospective assessment of MR-guided single-fraction stereotactic ablative radiotherapy for peripheral lung metastases: dosimetric and clinical outcomes","author":"Hering","year":"2025","journal-title":"Pract Radiat Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2025.101030_b0100","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/jamaoncol.2023.3495","article-title":"Individualized stereotactic ablative radiotherapy for lung tumors: the iSABR phase 2 nonrandomized controlled trial","volume":"9","author":"Gensheimer","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2025.101030_b0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2019.02.047","article-title":"Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): indirect cell death","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2025.101030_b0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother Oncol."},{"issue":"1","key":"10.1016\/j.ctro.2025.101030_b0115","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1245\/s10434-015-4579-z","article-title":"A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases","volume":"23","author":"Meyer","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctro.2025.101030_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.03.030","article-title":"Stereotactic magnetic resonance guided adaptive radiation therapy in one fraction: a multicenter, single-arm, phase 2 trial","author":"Chuong","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ctro.2025.101030_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187390","article-title":"Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ctro.2025.101030_b0130","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.brachy.2019.08.003","article-title":"Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies","volume":"18","author":"Hass","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ctro.2025.101030_b0135","article-title":"HDR brachytherapy versus robotic-based and linac-based stereotactic ablative body radiotherapy in the treatment of liver metastases - a dosimetric comparison study of three radioablative techniques","volume":"48","author":"Bilski","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2025.101030_b0140","article-title":"Radiation therapy for colorectal liver metastasis: the effect of radiation therapy dose and chemotherapy on local control and survival","volume":"9","author":"Chen","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101030_b0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fonc.2012.00023","article-title":"Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors","volume":"2","author":"Lanciano","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2025.101030_b0150","article-title":"Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer","volume":"14(1):453-60","author":"Doi","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctro.2025.101030_b0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1748-717X-6-34","article-title":"Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control","volume":"6","author":"Stinauer","year":"2011","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2025.101030_b0160","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2025.101030_b0165","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/hepr.12383","article-title":"Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma","volume":"45","author":"Sanuki","year":"2015","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.ctro.2025.101030_b0170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.01.221","article-title":"Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma","volume":"97","author":"Velec","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2025.101030_b0175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ijrobp.2009.09.009","article-title":"Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication","volume":"78","author":"Son","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.101030_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109576","article-title":"Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial","volume":"182","author":"Eufemon Cereno","year":"2023","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2025.101030_b0185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13014-023-02340-2","article-title":"Review of cone beam computed tomography based online adaptive radiotherapy: current trend and future direction","volume":"18","author":"Liu","year":"2023","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2025.101030_b0190","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.230011","article-title":"Adaptive radiation therapy: a review of CT-based techniques","volume":"5","author":"Lavrova","year":"2023","journal-title":"Radiol Imaging Cancer"},{"key":"10.1016\/j.ctro.2025.101030_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.prro.2025.02.011","article-title":"Practical approach to computed tomography guided online adaptive radiation therapy for abdominopelvic tumors","author":"Horowitz","year":"2025","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2025.101030_b0200","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ijrobp.2025.03.061","article-title":"Computed tomography-guided online adaptive stereotactic body radiation therapy for liver tumors: a retrospective study","volume":"122","author":"Lukez","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2025.101030_b0205","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ijrobp.2022.05.035","article-title":"Planning trade-offs for SABR in patients with 4 to 10 metastases: a substudy of the SABR-COMET-10 randomized trial","volume":"114","author":"Ashram","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825001223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825001223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:37:31Z","timestamp":1787729851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630825001223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"alternative-id":["S2405630825001223"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2025.101030","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of target volume coverage and liver exposure in high-dose-rate interstitial brachytherapy and in silico MR LINAC-based stereotactic body radiotherapy plans for colorectal liver metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2025.101030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101030"}}